Case Studies Archives - TrialAssure

The following case study is based on real work conducted between TrialAssure, MMS, and a top 10 pharma sponsor to accelerate the development of Clinical Study Reports using TrialAssure LINK AI. Problem A top 10 global pharma company launched a challenge to evaluate AI-augmented medical writing for Draft 1 Clinical Study Reports (CSRs). The AI system was required to operate fully within the sponsor’s secure cloud environment and integrate with its proprietary Large Language Model (LLM) under strict governance requirements. The timeline was compressed. After receiving protocols, SAPs, and an extensive list of TLFs, the team had a narrow window to generate both a Draft 1 CSR and Plain Language Summary (PLS). The challenge demanded an unprecedented level of speed and technical precision, with just three (3) days to set up the technical environment and five (5) days to complete the actual document drafts. Solution Using its AI-assisted authoring platform, LINK AI, TrialAssure was selected as one of just a few providers to participate in this program, partnering with MMS, a data-focused CRO, to rapidly deploy the solution within the sponsor’s cloud environment. The team seamlessly integrated the platform with the sponsor’s approved LLMs, configured a structured, AI-driven workflow, and securely ingested sponsor-provided source documents within an accelerated implementation timeline. Our medical writers accessed the sponsor environment to review outputs, refine prompts in real time, and strengthen complex results sections. The team integrated PLS development into the same workflow and produced English, French, and German versions. Then, our technical team addressed deployment and model integration challenges quickly, combining AI acceleration with experienced human oversight. “The team brought strong technical knowledge and medical writing experience together in a way that felt seamless. We were impressed by how responsive the team was, and the improvements made over a short period gave us confidence in its long-term potential.” Results The team successfully delivered a full Draft 1 CSR and PLSs in three (3) languages within just 24 hours of receiving source documents. Additionally, we were able to: Strengthen and expand the CSR template and prompt library. Provide rapid output improvements within mere days. Prove the successful deployment inside a controlled enterprise environment. Position a clear pathway for future enterprise AI-assisted medical writing initiatives. This challenge demonstrated that AI-augmented medical writing with TrialAssure’s LINK AI can function effectively within the strict infrastructure of any pharmaceutical and biotech organization.

Accelerating AI-Augmented CSR Development for a Top Global Biopharma Sponsor

by Staff Writer | April 2026

Posted in Blog, Case Studies

Read More

How Daiichi Sankyo Accelerated Plain Language Summary Development with TrialAssure LINK AI

How Daiichi Sankyo Accelerated Plain Language Summary Development with TrialAssure LINK AI

by Staff Writer | January 2026

Posted in Blog, Case Studies

Read More

TrialAssure and Certara Anonymisation Technology Tool Partnership

How Certara and TrialAssure Partner to Deliver Faster, Compliant Anonymisation for Global Sponsors

by Staff Writer | April 2025

Posted in Blog, Case Studies

Read More

GenAI to create Informed Consent Forms (ICFs)

How MMS and TrialAssure Engaged AI to Improve the Quality and Delivery in Producing Informed Consent Forms (ICFs) and other Regulatory Documents

by Staff Writer | February 2025

Posted in Blog, Case Studies

Read More

The following is a case study based on real work conducted between TrialAssure and one of its trusted sponsor partners. Problem A clinical stage biotech company, sought to share their clinical trial datasets voluntarily with research partners for secondary analyses and derivative research. However, they faced significant challenges, including the high risk of re-identification due to a small patient population that makes traditional qualitative anonymization insufficient. Additionally, they needed to protect patient privacy while preserving the data's utility for meaningful research, as well as maintain compliance with varying global regulatory requirements. To address these complexities, they sought an experienced partner capable of delivering quantitative, evidence-based anonymization. Solution TrialAssure, with its industry-leading AI-powered platform ANONYMIZE, was selected as the ideal partner to meet these challenges. Leveraging over a decade of experience in clinical data transparency and anonymization, TrialAssure delivered a comprehensive solution tailored to their needs, starting with a risk-based anonymization approach. TrialAssure ANONYMIZE employed a sophisticated quantitative anonymization strategy to achieve measurable re-identification risk thresholds while maintaining optimal data utility. Through TrialAssure’s quick and efficient processes, the end-to-end project, encompassing risk analysis, anonymization, and reporting, was completed approximately 80 percent faster. On top of the anonymized dataset, TrialAssure provided a detailed Data Anonymization Report and Data Specification Report to ensure visibility into the anonymization process, support informed decision-making, and demonstrate compliance with regulatory standards. Additionally, TrialAssure ANONYMIZE acted as a secure data exchange platform, enabling seamless and protected data sharing with the clinical-stage biotech’s research partners.

How a Clinical-Stage Biotech Accelerated Secure Clinical Trial Data Sharing 80% Faster with TrialAssure

by Staff Writer | February 2025

Posted in Blog, Case Studies

Read More

Get in Touch